Intermediate · 12-26 weeks
Tesamorelin Clinical Standard
FDA-approved dose: 2mg daily SC (abdomen). The gold standard for visceral fat reduction via pulsatile GH release. Assess results at 12 weeks. Up to 26 weeks in clinical trials.
- Type
- single
- Source
- evidence-based
- Pattern
- Continuous during treatment course. Assess at 12 weeks.
Compounds
Tesamorelin
SC · Evening/before bed (aligns with GH circadian rhythm). Abdomen injection site per label.
SC · Evening/before bed (aligns with GH circadian rhythm). Abdomen injection site per label.
2 mg
daily
daily
Notes
Supply: 2mg/day × 84 days (12 weeks) = 168mg → 84 × 2mg vials. This is THE subscription product — monthly auto-ship essential. Monitor IGF-1 levels. Visceral fat reduction measurable at 12 weeks.
Source notes
FDA-approved as Egrifta for HIV lipodystrophy. FDA label: 2mg SC daily. PMID: 25105358. Mayo Clinic, MedlinePlus, Drugs.com all reference 2mg/day.
For research and educational use only. This content is not medical advice.